KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Rigel Pharmaceuticals (RIGL) over the last 13 years, with Dec 2024 value amounting to $26,000.

  • Rigel Pharmaceuticals' Capital Expenditures was N/A to $26,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $252,000, marking a year-over-year change of. This contributed to the annual value of $36,000 for FY2024, which is N/A change from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Capital Expenditures of $26,000 as of Q4 2024, which was down 64.38% from $73,000 recorded in Q4 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' Capital Expenditures peaked at $607,000 during Q1 2020, and registered a low of -$44,000 during Q2 2020.
  • Moreover, its 2-year median value for Capital Expenditures was $73,000 (2022), whereas its average is $95,200.
  • In the last 5 years, Rigel Pharmaceuticals' Capital Expenditures tumbled by 138.26% in 2020 and then surged by 1,025.00% in 2021.
  • Rigel Pharmaceuticals' Capital Expenditures (Quarterly) stood at $504,000 in 2020, then slumped by 104.17% to -$21,000 in 2021, then surged by 447.62% to $73,000 in 2022, then reached $26,000 in 2024.
  • Its last three reported values are $26,000 in Q4 2024, $73,000 for Q4 2022, and $189,000 during Q3 2022.